Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
$13.75 -0.07 (-0.51%)
As of 03/01/2021 15:59:57 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.